CNBC
01 Jun 2026, 14:00 UTC · 2h ago
Why Trump Is Pushing Psychedelics To Treat Mental Illness
Search tags
CNBC
01 Jun 2026, 14:00 UTC · 2h ago
Search tags
Story key points
2 claims · impact-rated
Compass Pathways, Transcend Therapeutics, and Usona Institute have received priority FDA review vouchers via executive order. — Priority review significantly accelerates the timeline to commercialization and revenue for these specific biotech firms.
+0.80The Trump administration is pushing to fast-track the approval of psychedelic drugs. — A systemic policy shift toward faster approvals increases the overall addressable market and risk appetite for the psychedelic sector.
+0.50Ticker attribution
Model heads
The company received a priority FDA review voucher, which significantly accelerates the drug approval process.
Continue reading
6 related stories
[mutual] Both companies are developing psychedelic drugs and received priority FDA review vouchers.
[mutual] Both companies are developing psychedelic drugs and received priority FDA review vouchers.
[mutual] Both companies are developing psychedelic drugs and received priority FDA review vouchers.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Benzinga
14h ago
